{
  "url": "https://www.marketwatch.com/story/biogen-eisai-get-fda-approval-for-injectable-alzheimer-s-treatment-8fb80d76",
  "authorsByline": "",
  "articleId": "c40a6d424361400d94122747ae209374",
  "source": {
    "domain": "marketwatch.com",
    "paywall": true,
    "location": {
      "country": "us",
      "state": "CA",
      "county": "San Francisco",
      "city": "San Francisco",
      "coordinates": {
        "lat": 37.7790262,
        "lon": -122.419906
      }
    }
  },
  "imageUrl": "",
  "country": "us",
  "language": "en",
  "pubDate": "2025-08-29T21:40:00+00:00",
  "addDate": "2025-08-29T21:46:31.411476+00:00",
  "refreshDate": "2025-08-29T21:46:31.411477+00:00",
  "score": 1.0,
  "title": "Biogen, Eisai Get FDA Approval for Injectable Alzheimer's Treatment",
  "description": "Biogen, Eisai Get FDA Approval for Injectable Alzheimer's Treatment",
  "content": "Biogen and Eisai said federal regulators have approved a once-weekly injectable version of their Alzheimer's treatment Leqembi.\n\nThe Food and Drug Administration's approval will allow the Leqembi Iqlik autoinjector to be launched in the U.S. on Oct. 6.\n\nThe jab is intended for Alzheimer's disease patients with mild cognitive impairment or mild dementia stage of disease.\n\nAfter 18 months of traditional intravenous Leqembi treatment every two weeks, patients can now either continue with the IV infusions every four weeks or start using Leqembi Iqlik each week.\n\nThe FDA first approved Leqembi in 2023. It has since been approved in the U.K., Japan, China and other countries.",
  "medium": "Article",
  "links": [],
  "labels": [],
  "claim": "",
  "verdict": "",
  "keywords": [
    {
      "name": "Leqembi Iqlik",
      "weight": 0.14180346
    },
    {
      "name": "traditional intravenous Leqembi treatment",
      "weight": 0.13818759
    },
    {
      "name": "FDA Approval",
      "weight": 0.11810388
    },
    {
      "name": "Leqembi",
      "weight": 0.118032925
    },
    {
      "name": "mild cognitive impairment",
      "weight": 0.10595981
    },
    {
      "name": "mild dementia stage",
      "weight": 0.10395638
    },
    {
      "name": "patients",
      "weight": 0.09351687
    },
    {
      "name": "federal regulators",
      "weight": 0.09143247
    },
    {
      "name": "the Leqembi Iqlik autoinjector",
      "weight": 0.085107006
    },
    {
      "name": "FDA",
      "weight": 0.08363809
    }
  ],
  "topics": [
    {
      "name": "Markets"
    },
    {
      "name": "FDA"
    }
  ],
  "categories": [
    {
      "name": "Finance"
    },
    {
      "name": "Health"
    }
  ],
  "taxonomies": [
    {
      "name": "/News/Health News",
      "score": 0.94482421875
    },
    {
      "name": "/Health/Pharmacy/Drugs & Medications",
      "score": 0.85693359375
    },
    {
      "name": "/Business & Industrial/Pharmaceuticals & Biotech",
      "score": 0.8232421875
    },
    {
      "name": "/Health/Medical Literature & Resources/Other",
      "score": 0.56494140625
    },
    {
      "name": "/Health/Health Foundations & Medical Research",
      "score": 0.50830078125
    },
    {
      "name": "/News/Business News/Company News",
      "score": 0.4970703125
    }
  ],
  "sentiment": {
    "positive": 0.4308319,
    "negative": 0.04026976,
    "neutral": 0.5288983
  },
  "summary": "The US Food and Drug Administration has approved a once-weekly injectable version of Biogen's Alzheimer's treatment, Leqembi. The injection is intended for patients with mild cognitive impairment or mild dementia. The approval will allow for the launch of the product in the U.S. after 18 months of traditional intravenous treatment.",
  "shortSummary": "Biogen and Eisai's Leqemperate have secured FDA approval for a once-weekly injectable version of their Alzheimer's treatment, known as \"The Devil\" (or \"The Beast)",
  "translation": "",
  "translatedTitle": "",
  "translatedDescription": "",
  "translatedSummary": "",
  "reprint": false,
  "reprintGroupId": "61c9410fe37e484f87fddb92a6b928c7",
  "places": [],
  "scraped_sources": [],
  "argos_summary": "Biogen and Eisai said federal regulators have approved a once-weekly injectable version of their Alzheimer's treatment Leqembi.\n\nThe Food and Drug Administration's approval will allow the Leqembi Iqlik autoinjector to be launched in the U.S. on Oct. 6.\n\nThe jab is intended for Alzheimer's disease patients with mild cognitive impairment or mild dementia stage of disease.\n\nAfter 18 months of traditional intravenous Leqembi treatment every two weeks, patients can now either continue with the IV inf...",
  "argos_id": "NKSSQTLSS"
}